Skip to main content
Newron Pharmaceuticals S.p.A. logo

Newron Pharmaceuticals S.p.A. — Investor Relations & Filings

Ticker · NWRN ISIN · IT0004147952 LEI · 8156002F8C11F80A9740 SW Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2025-12-08 Regulatory Filings
Country IT Italy
Listing SW NWRN

About Newron Pharmaceuticals S.p.A.

https://www.newron.com/

Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.

Recent filings

Filing Released Lang Actions
EQS-News: Newron gibt US-Start der globalen klinischen Phase-III-Studie ENIGMA-TRS 2 mit Evenamide als Zusatztherapie für Patienten mit behandlungsresistenter Schizophrenie (TRS) bekannt
Regulatory Filings Classification · 95% confidence The document is a press release issued by Newron Pharmaceuticals announcing the start of a Phase III clinical trial (ENIGMA-TRS 2). It provides details on the study design, the drug candidate (Evenamide), and the medical context of the trial. It does not fit into financial reporting categories like 10-K or IR, nor is it a report publication announcement (RPA) as it is the primary announcement of the event itself. As it is a corporate announcement regarding business operations and clinical development, it falls under the 'Regulatory Filings' (RNS) category as a general corporate news release.
2025-12-08 German
Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically Luca Benatti, a member of the administrative body of Newron Pharmaceuticals S.p.A. It details the disposal of shares, the price, volume, and the date of the transaction. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-12-03 English
Newron Pharmaceuticals S.p.A.: Luca Benatti, sell
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically Luca Benatti, a member of the administrative body of Newron Pharmaceuticals S.p.A. It details the disposal of shares, the price, volume, and the date of the transaction. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2025-11-27 English
Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Regulatory Filings Classification · 100% confidence The document is a corporate press release issued by Newron Pharmaceuticals S.p.A. announcing that the company will present clinical trial data and updates regarding its drug candidate 'evenamide' at an upcoming medical congress (38th ECNP Congress). It does not contain financial statements, audit reports, or regulatory filings, but rather serves as a standard corporate news announcement regarding research and development progress. As it does not fit into specific categories like 10-K, ER, or IP (which would be a slide deck), it falls under the general regulatory/corporate news category.
2025-10-02 English
EQS-News: Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Regulatory Filings Classification · 100% confidence The document is a corporate press release issued by Newron Pharmaceuticals S.p.A. announcing that the company will present clinical trial data and updates regarding its drug candidate 'evenamide' at an upcoming medical congress (38th ECNP Congress). It does not contain the actual financial report, audit, or proxy materials, but rather serves as a public announcement of company activities and research progress. As it does not fit into specific categories like 'Earnings Release' (which would focus on quarterly financial results) or 'Investor Presentation' (which would be the slide deck itself), it is classified as a general regulatory/corporate announcement.
2025-10-02 English
EQS-News: Newron präsentiert neue Analysen und Updates zu seinem klinischen Programm zur Bewertung von Evenamide als Zusatztherapie bei Schizophrenie auf dem 38. Kongress des ECNP 2025
Regulatory Filings Classification · 100% confidence The document is a corporate press release issued via EQS News. It announces that Newron Pharmaceuticals will present new clinical data and updates regarding its drug candidate 'Evenamide' at an upcoming medical congress (ECNP 2025). It provides a summary of clinical trial results and future study plans but does not constitute a full financial report, audit, or regulatory filing. As it is a standard corporate announcement regarding research and development progress, it falls under the 'Regulatory Filings' (RNS) category as a general corporate news release.
2025-10-02 German

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.